These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 33367861)
1. Effects of bisphosphonates on long-term kidney transplantation outcomes. Song SH; Choi HY; Kim HY; Nam CM; Jeong HJ; Kim MS; Kim SII; Kim YS; Huh KH; Kim BS Nephrol Dial Transplant; 2021 Mar; 36(4):722-729. PubMed ID: 33367861 [TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates for prevention of osteopenia in kidney-transplant recipients: a systematic review of randomized controlled trials. Wang J; Yao M; Xu JH; Shu B; Wang YJ; Cui XJ Osteoporos Int; 2016 May; 27(5):1683-90. PubMed ID: 26733377 [TBL] [Abstract][Full Text] [Related]
3. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort. Segaud N; Legroux I; Hazzan M; Noel C; Cortet B Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526 [TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates and bone fractures in long-term kidney transplant recipients. Conley E; Muth B; Samaniego M; Lotfi M; Voss B; Armbrust M; Pirsch J; Djamali A Transplantation; 2008 Jul; 86(2):231-7. PubMed ID: 18645484 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Bisphosphonates for Osteoporosis or Osteopenia in Cardiac Transplant Patients: A Meta-Analysis. Zhao J; Wang C; Hu Z Transplant Proc; 2015 Dec; 47(10):2957-64. PubMed ID: 26707321 [TBL] [Abstract][Full Text] [Related]
6. Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial. van Hellemond IEG; Smorenburg CH; Peer PGM; Swinkels ACP; Seynaeve CM; van der Sangen MJC; Kroep JR; de Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; de Roos WK; Linn SC; Imholz ALT; de Boer M; Tjan-Heijnen VCG; Breast Cancer Res Treat; 2020 Apr; 180(3):675-685. PubMed ID: 32124136 [TBL] [Abstract][Full Text] [Related]
7. Outcomes of bisphosphonate therapy in kidney transplant recipients: a systematic review and meta-analysis. Toth-Manikowski SM; Francis JM; Gautam A; Gordon CE Clin Transplant; 2016 Sep; 30(9):1090-6. PubMed ID: 27327448 [TBL] [Abstract][Full Text] [Related]
8. Ibandronate in stable renal transplant recipients with low bone mineral density on long-term follow-up. Tillmann FP; Schmitz M; Jäger M; Krauspe R; Rump LC Int Urol Nephrol; 2016 Feb; 48(2):279-86. PubMed ID: 26498632 [TBL] [Abstract][Full Text] [Related]
9. Outcomes of bisphosphonate and its supplements for bone loss in kidney transplant recipients: a systematic review and network meta-analysis. Yang Y; Qiu S; Deng L; Tang X; Li X; Wei Q; Fu P BMC Nephrol; 2018 Oct; 19(1):269. PubMed ID: 30340537 [TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates for osteoporosis in people with cystic fibrosis. Conwell LS; Chang AB Cochrane Database Syst Rev; 2012 Apr; (4):CD002010. PubMed ID: 22513903 [TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. Ito K; Blinder VS; Elkin EB J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313 [TBL] [Abstract][Full Text] [Related]
12. Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients. Geller JL; Hu B; Reed S; Mirocha J; Adams JS Endocr Pract; 2008 Apr; 14(3):293-7. PubMed ID: 18463035 [TBL] [Abstract][Full Text] [Related]
13. Effects of bisphosphonates on bone loss in the first year after renal transplantation--a meta-analysis of randomized controlled trials. Mitterbauer C; Schwarz C; Haas M; Oberbauer R Nephrol Dial Transplant; 2006 Aug; 21(8):2275-81. PubMed ID: 16574684 [TBL] [Abstract][Full Text] [Related]
14. Impact of monocyte-macrophage inhibition by ibandronate on graft function and survival after kidney transplantation: a single-centre follow-up study over 15 years. Tillmann FP; Grotz W; Rump LC; Pisarski P Clin Exp Nephrol; 2018 Apr; 22(2):474-480. PubMed ID: 28856476 [TBL] [Abstract][Full Text] [Related]
15. Bone Mineral Density and Bone Turnover Markers Under Bisphosphonate Therapy Used in the First Year After Liver Transplantation. Nowacka-Cieciura E; Sadowska A; Pacholczyk M; Chmura A; Tronina O; Durlik M Ann Transplant; 2016 Apr; 21():241-9. PubMed ID: 27112626 [TBL] [Abstract][Full Text] [Related]
16. Bone density in heart or lung transplant recipients--a longitudinal study. Wang TK; O'Sullivan S; Gamble GD; Ruygrok PN Transplant Proc; 2013; 45(6):2357-65. PubMed ID: 23747143 [TBL] [Abstract][Full Text] [Related]
17. [InoPro trial: collaboration between urologists and primary care physicians in the treatment of osteoporosis in prostate cancer patients]. Laufer M; Keller T; Gershman V; Ferman Z; Sarid M; Leibovitch I Harefuah; 2014; 153(3-4):151-4, 240. PubMed ID: 24791553 [TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis. Ding H; Yang L; Du W; Teng Y; Fu SJ; Tao Y; Lu JZ; Wang ZP Asian Pac J Cancer Prev; 2013; 14(5):3337-43. PubMed ID: 23803126 [TBL] [Abstract][Full Text] [Related]
19. Interventions for preventing bone disease in kidney transplant recipients. Palmer SC; McGregor DO; Strippoli GF Cochrane Database Syst Rev; 2007 Jul; (3):CD005015. PubMed ID: 17636784 [TBL] [Abstract][Full Text] [Related]